Curis Inc. Daily Stock Analysis

Daily Stock Analysis, CRIS, Curis Inc, priceseries

Curis Inc. Daily Stock Analysis
Stock Information
Open
3.00
Close
2.93
High
3.04
Low
2.85
Previous Close
2.96
Daily Price Gain
-0.03
YTD High
5.27
YTD High Date
Jan 5, 2022
YTD Low
2.78
YTD Low Date
Feb 24, 2022
YTD Price Change
-2.20
YTD Gain
-42.88%
52 Week High
17.40
52 Week High Date
May 12, 2021
52 Week Low
2.78
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-6.04
52 Week Gain
-67.34%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 8. 2017
12.75
Mar 21. 2017
14.31
9 Trading Days
12.25%
Link
LONG
Jun 16. 2017
8.85
Jun 29. 2017
10.00
9 Trading Days
12.94%
Link
LONG
Aug 28. 2017
8.85
Sep 11. 2017
9.87
9 Trading Days
11.48%
Link
LONG
Mar 2. 2018
2.62
Mar 16. 2018
3.74
10 Trading Days
42.79%
Link
LONG
Aug 31. 2018
1.70
Sep 4. 2018
1.79
1 Trading Days
5.00%
Link
LONG
Jan 14. 2019
0.96
Jan 28. 2019
1.13
9 Trading Days
17.96%
Link
LONG
Mar 11. 2019
1.12
Apr 10. 2019
2.14
22 Trading Days
91.34%
Link
LONG
Jun 14. 2019
1.46
Jul 3. 2019
1.74
13 Trading Days
19.44%
Link
LONG
Jul 5. 2019
1.79
Jul 18. 2019
2.16
9 Trading Days
20.80%
Link
LONG
Jun 8. 2020
0.86
Jun 22. 2020
1.12
10 Trading Days
30.00%
Link
LONG
Nov 11. 2020
1.21
Dec 7. 2020
1.58
17 Trading Days
30.21%
Link
LONG
Dec 8. 2020
6.55
Jan 22. 2021
11.04
30 Trading Days
68.50%
Link
LONG
Aug 23. 2021
7.67
Sep 7. 2021
8.20
10 Trading Days
6.85%
Link
Company Information
Stock Symbol
CRIS
Exchange
NasdaqGM
Company URL
http://www.curis.com
Company Phone
617-503-6500
CEO
Ali Fattaey
Headquarters
Massachusetts
Business Address
4 MAGUIRE ROAD, LEXINGTON, MA 02421
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001108205
About

Curis, Inc. is a biotechnology company, which is focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Its pipeline includes is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase, or HDAC, and phosphatidylinositol-3-kinase, or PI3K enzymes. It conducts research programs both internally and through strategic collaborations. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Description

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading